Bifidobacterium longum

Structure & Biochemistry

Taxonomy	Domain Bacteria → Phylum Actinobacteria → Class Actinobacteria → Order Bifidobacteriales → Family Bifidobacteriaceae → Bifidobacterium longum (four subspecies: longum, infantis, suis, suillum)
Key subspecies	B. l. subsp. infantis — infant gut specialist, HMO consumer, EV genomes differ ~20% from subsp. longum; B. l. subsp. longum — adult gut resident, plant polysaccharide specialist; different ecologies and gene repertoires
Cell morphology	Irregular (bifid) Y-shaped or branching rod, 0.5–1.3 µm × 1.5–8 µm; highly variable morphology (basis of "bifid" name); Gram-positive; non-motile; non-spore-forming; strictly anaerobic in natural habitat
Bifidus shunt (fructose-6-phosphate phosphoketolase pathway)	Unique to Bifidobacterium genus; 2.5 ATP/glucose vs 2 ATP from glycolysis; ferments hexoses → acetate + lactate (ratio ~3:2); avoids formate/ethanol byproducts; characteristic "bifidum" fermentation profile detectable in stool NMR
HMO utilisation cluster (B. infantis)	~43 kb gene cluster encoding sialidases, fucosidases, lacto-N-biosidases, β-galactosidases for internalising and catabolising all major HMO classes (sialylated, fucosylated, core structures); imported intact into cell via ABC transporters (intracellular digestion — reduces pathogen cross-feeding vs extracellular degradation)
Lacto-N-biosidase (LnbB)	Key enzyme cleaving the lacto-N-tetraose core of type 1 HMOs; highly expressed during infant colonisation; responsible for ~40% of HMO consumption by B. infantis; structural conservation across B. infantis strains
Genome (B. l. infantis ATCC 15697)	~2.8 Mb; HMO cluster is largest unique region vs B. l. longum; 2,588 ORFs; GC content ~60%; carries plasmid with additional carbohydrate metabolism genes; streamlined compared to other gut bacteria
Indole production	B. longum subsp. longum produces indole-3-lactic acid (ILA) from tryptophan; ILA activates AHR (aryl hydrocarbon receptor) on ILC3 and T cells → IL-22 induction → antimicrobial peptide production and gut barrier reinforcement

Mechanisms of Benefit

• HMO consumption → bifidogenic environment (B. infantis) Human milk oligosaccharides (HMOs) constitute the third most abundant component of breast milk but are completely indigestible by the infant. B. infantis is evolutionarily optimised to consume HMOs via intracellular import — sequestering HMO sugars from competitor bacteria and producing acetate + lactate. The resulting acidic, acetate-rich intestinal environment (pH ~5.5) suppresses Enterobacteriaceae growth, reduces LPS load, and creates a bifidogenic niche. Breastfed infants colonised by B. infantis have dramatically reduced pathogen carriage and infection rates vs formula-fed infants.
• Immune programming of the neonatal gut B. infantis colonisation is not merely metabolic — it directly educates the developing mucosal immune system. During the critical neonatal window, B. infantis cell surface components (LTA, EPS) activate pattern recognition receptors on immature DCs and enterocytes → tolerogenic cytokine milieu (IL-10, TGF-β) → FoxP3+ Treg priming. Clinical data: breastfed infants colonised by B. infantis show reduced IL-6 and calprotectin (intestinal inflammation markers) and lower prevalence of allergic disease at 1 year vs matched non-colonised infants.
• Acetate production → gut barrier protection Acetate (primary B. infantis/longum fermentation product) protects against enteropathogen-induced barrier disruption. Mechanistically: acetate prevents host cell apoptosis via an as-yet incompletely characterised anti-apoptotic signalling pathway; reduces translocation of Shiga toxin from E. coli O157:H7 in mouse models by 100-fold. Acetate also serves as the primary cross-feeding substrate for Faecalibacterium prausnitzii → butyrate → colonocyte energy.
• Sialylated HMO catabolism → sialic acid recycling B. infantis releases sialic acid from sialylated HMOs; sialic acid is taken up by intestinal cells and incorporated into gangliosides and glycoproteins in the developing brain (neonatal neurological maturation). This molecular mechanism — milk oligosaccharides → microbiome catabolism → host brain nutrition — represents a unique example of microbiome-mediated developmental support.
• Indole-3-lactic acid → AHR → IL-22 (B. l. longum adult) In adults, B. longum subsp. longum produces ILA from tryptophan; ILA activates the aryl hydrocarbon receptor (AHR) on intestinal ILC3 cells and CD4+ T cells → IL-22 production → induction of REG3γ and REG3β antimicrobial proteins and mucin upregulation. This pathway is independent of HMO metabolism and represents the adult subspecies' primary immunoregulatory mechanism.

Microbiome Context

Clinical Associations

Condition / Life Stage	Association	Evidence	Status
Breastfed infant gut health	B. infantis dominance (up to 90% of microbiome) correlates with lower infection risk, reduced intestinal inflammation markers, and better stool pH; formula-fed infants lack B. infantis	Multiple cohorts	Strongly beneficial
Infant eczema / allergy prevention	Early B. infantis colonisation associated with reduced atopic sensitisation at 1 year; interaction with HMO type (sialylated HMOs most protective)	Observational + intervention	Promising
Necrotising Enterocolitis (preterm infants)	Absence of B. infantis is a consistent risk factor for NEC in preterm neonates; supplementation trials show reduced NEC incidence; mechanism: reduced LPS load from Gram-negatives	RCT + cohort evidence	Protective (preterm)
Adult gut health & IBD	B. l. longum depleted in IBD, IBS, and metabolic disease; supplementation reduces systemic inflammation markers (CRP); brain–gut evidence for stress and anxiety modulation	RCTs (multiple indications)	Moderate evidence
Age-related decline	B. longum abundance declines markedly with age; elderly low-Bifidobacterium microbiomes associate with frailty and increased infection susceptibility; restoration by supplementation being tested	Cross-sectional studies	Declines with age

Research & Therapeutic Status

• B. infantis EVC001 — infant probiotic (Evivo) Commercial product (Evolve BioSystems) containing 8×10⁹ CFU of B. l. subsp. infantis EVC001 per dose. Designed to restore B. infantis colonisation in formula-fed or antibiotic-exposed infants. RCT (Smilowitz et al. 2017, n=66): EVC001 colonisation established in 90% of treated infants; reduced Enterobacteriaceae 4-log, reduced faecal LPS 6-fold, reduced intestinal inflammation (calprotectin, IL-6). FDA GRAS; registered in USA and Europe.
• B. longum subsp. longum NCC3001 — psychobiotic Pivotal RCT (Pinto-Sanchez et al. 2017, n=44, IBS patients): B. longum NCC3001 10⁹ CFU/day × 6 weeks reduced depression scores (PHQ-9) vs placebo; reduced anxiety; correlated with changes in fMRI brain activity (limbic/prefrontal responses). Mechanism: vagus nerve signalling, ILA/AHR, and possibly direct tryptophan modulation. Replicated in part; psychobiotic research landscape expanding.
• NEC prevention in premature infants Several NICUs now use B. infantis-containing probiotic preparations as standard NEC prevention in preterm neonates <32 weeks. UK, Germany, and Australia NICU guidelines updated 2020–2023 to recommend Bifidobacterium-based prophylaxis. NNT for NEC prevention ~20–25 in very low birthweight infants (meta-analysis, Cochrane 2020).

Cross-Atlas Connections

References

• Sela DA et al. (2008). The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci USA 105(48):18964–9.
• Fukuda S et al. (2011). Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469(7331):543–7.
• Smilowitz JT et al. (2017). B. infantis EVC001 supplementation in exclusively breastfed infants. Pediatr Res 83:1–8.
• Pinto-Sanchez MI et al. (2017). Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity. Gastroenterology 153(2):448–59.
• Aceti A et al. (2015). Probiotics and time to achieve full enteral feeding in human milk-fed and formula-fed preterm infants. J Matern Fetal Neonatal Med 28(13):1513–9.
• Tannock GW et al. (2013). A new macrocosm: next-generation sequencing meets Bifidobacterium ecology. Appl Environ Microbiol 79(12):3593–605.